Kenneth Locke - Carisma Therapeutics Senior Operations
| CARM Stock | 0.85 0.01 1.19% |
Executive
Kenneth Locke is Senior Operations of Carisma Therapeutics
| Address | 3675 Market Street, Philadelphia, PA, United States, 19104 |
| Phone | 267 491 6422 |
| Web | https://www.carismatx.com |
Carisma Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5608) % which means that it has lost $0.5608 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6279) %, meaning that it created substantial loss on money invested by shareholders. Carisma Therapeutics' management efficiency ratios could be used to measure how well Carisma Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 3rd of December 2024, Return On Tangible Assets is likely to drop to -1.02. In addition to that, Return On Capital Employed is likely to drop to -1.27. At this time, Carisma Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 3rd of December 2024, Total Current Assets is likely to grow to about 84.5 M, while Total Assets are likely to drop about 65.7 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Gerhard Bauer | Immix Biopharma | N/A | |
| Michael Howell | Zura Bio Limited | 47 | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| Ben JD | Immix Biopharma | N/A | |
| Gary Whale | Zura Bio Limited | 50 | |
| MD FFPM | Immix Biopharma | 64 | |
| Covadonga Paneda | Altamira Therapeutics | 50 | |
| Mitchell MD | Palisade Bio | 46 | |
| Theresa Lowry | Zura Bio Limited | 50 | |
| Joerg Heyer | Palisade Bio | N/A | |
| Melda Oconnell | ZyVersa Therapeutics | N/A | |
| Kevin CPA | Enveric Biosciences | 60 | |
| Ryker Willie | Palisade Bio | N/A | |
| Kiran MBBS | Zura Bio Limited | 51 | |
| Verender Badial | Zura Bio Limited | 52 | |
| David Marks | Immix Biopharma | N/A | |
| John SullivanBolyai | Hepion Pharmaceuticals | 76 | |
| John Cavan | Hepion Pharmaceuticals | 66 | |
| David Brady | Zura Bio Limited | N/A | |
| Daniel Trepanier | Hepion Pharmaceuticals | N/A | |
| MD FACC | ZyVersa Therapeutics | 74 | |
Management Performance
| Return On Equity | -3.63 | ||||
| Return On Asset | -0.56 |
Carisma Therapeutics Leadership Team
Elected by the shareholders, the Carisma Therapeutics' board of directors comprises two types of representatives: Carisma Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Carisma. The board's role is to monitor Carisma Therapeutics' management team and ensure that shareholders' interests are well served. Carisma Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Carisma Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Terry Shields, Senior Resources | ||
| Kenneth Locke, Senior Operations | ||
| Steven Kelly, CEO President | ||
| Klichinsky PharmD, CoFounder Officer | ||
| MD FACS, Chief Officer | ||
| MBA JD, General Secretary | ||
| Tom Wilton, Chief Officer | ||
| Richard CPA, Chief CFO | ||
| Saar MD, CoFounder Board | ||
| Dr FCP, Chief Officer |
Carisma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Carisma Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.63 | ||||
| Return On Asset | -0.56 | ||||
| Operating Margin | (3.88) % | ||||
| Current Valuation | 12.1 M | ||||
| Shares Outstanding | 41.75 M | ||||
| Shares Owned By Insiders | 28.53 % | ||||
| Shares Owned By Institutions | 31.51 % | ||||
| Number Of Shares Shorted | 558.58 K | ||||
| Price To Book | 114.10 X | ||||
| Price To Sales | 1.76 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Carisma Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.493 | Quarterly Revenue Growth (0.12) | Return On Assets (0.56) | Return On Equity (3.63) |
The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Carisma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.